Rocio Martin Hoyos
Chief Strategy Officer · Atrium Therapeutics, Inc.
Individual
- 2026
- Sep 22, 2026
- 2
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Rocio Martin Hoyos's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Fairmount Funds Management LLC - $370.02M in COGT purchases and sales in the last 12 months
- August J. Troendle - $358.45M in MEDP purchases and sales in the last 12 months
- J.H. Whitney Equity Partners VII, LLC - $319.15M in AVAH purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $317.75M in CELC purchases and sales in the last 12 months
- A/S Genmab - $234.86M in MRUS purchases and sales in the last 12 months
- Weiss Asset Management LP - $233.35M in AVDL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Rocio Martin Hoyos?
Rocio Martin Hoyos is a corporate insider, tracked as Chief Strategy Officer of Atrium Therapeutics, Inc. (RNA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Rocio Martin Hoyos submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
